<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333760</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-WAS-03</org_study_id>
    <nct_id>NCT02333760</nct_id>
  </id_info>
  <brief_title>Gene Therapy for WAS Follow-up</brief_title>
  <acronym>WAS FUP</acronym>
  <official_title>Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open follow up study of patients enrolled in the Phase 1/2 clinical trial of
      haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with
      autologous CD34+ cells transduced with the w1.6_hWASP_WPRE (VSVg) lentiviral vector.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of SAEs</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence and nature of delayed events such as malignancies, hematologic, autoimmune events, mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lentiviral integration sites</measure>
    <time_frame>36 months</time_frame>
    <description>Presence of lentiviral integration sites in different cells sub-populations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vector copy numbers</measure>
    <time_frame>36 months</time_frame>
    <description>Quantification of vector copy numbers on sorted cells population by q-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Replication competent lentivirus (RCL)</measure>
    <time_frame>36 months</time_frame>
    <description>Presence of RCL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in medical conditions</measure>
    <time_frame>36 months</time_frame>
    <description>Weight and complete clinical exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Key medical events related to WAS</measure>
    <time_frame>36 months</time_frame>
    <description>Eczema status, infections, bleeding symptoms, autoimmune manifestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematological reconstitution</measure>
    <time_frame>36 months</time_frame>
    <description>CBC including platelets count and size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reconstitution of cell mediated and humoral immunity</measure>
    <time_frame>36 months</time_frame>
    <description>Immunophenotyping panel, whole blood lymphocytes proliferation assays, restoration of antibody production, humoral response to antigene</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for associated treatments</measure>
    <time_frame>36 months</time_frame>
    <description>Immunoglobulins, antibacterial, antifungal, antiviral drugs, transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Representation of TCR families</measure>
    <time_frame>36 months</time_frame>
    <description>Representation of TCR families by PCR TREC (TCR excision circle) and TCR V beta panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow content</measure>
    <time_frame>36 months</time_frame>
    <description>Numbers and type of cells in bone marrow</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous CD34+ cells transduced with WASP lentiviral vector</intervention_name>
    <description>Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients enrolled in the initial phase I/II WAS conducted in France and United Kingdom
             (GTG002.07 and GTG003.08).

          -  Parents, guardians or patient signed informed consent, guardians or patient signed
             informed consent

        Exclusion Criteria:

        â€¢ Parents, guardians, patients unwilling to return for the follow up study period.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Cavazzana, MD, PHD</last_name>
      <phone>+33 (0)1 44 49 50 68</phone>
      <email>m.cavazzana@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marina Cavazzana, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Institute of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Thrasher, MD, PHD</last_name>
      <phone>+44(0) 207 905 2660</phone>
      <email>A.Thrasher@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Adrian Thrasher, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

